{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:49:40Z","timestamp":1792648180102,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07158-y","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:54:17Z","timestamp":1760450057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yixin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-5152","authenticated-orcid":false,"given":"Ning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"no. 1","key":"7158_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"7158_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074962","author":"N Deboever","year":"2024","unstructured":"Deboever N, Jones CM, Yamashita K, Ajani JA, Hofstetter WL. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024. https:\/\/doi.org\/10.1136\/bmj-2023-074962.","journal-title":"BMJ"},{"issue":"27","key":"7158_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796\u2013803. https:\/\/doi.org\/10.1200\/JCO.2018.79.1483.","journal-title":"J Clin Oncol"},{"key":"7158_CR4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0019","author":"A Ja","year":"2023","unstructured":"Ja A, et al. Esophageal and esophagogastric junction cancers, version 2.2023 NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2023. https:\/\/doi.org\/10.6004\/jnccn.2023.0019.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"issue":"3","key":"7158_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343\u201372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2.","journal-title":"Esophagus"},{"issue":"5","key":"7158_CR6","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367. https:\/\/doi.org\/10.1016\/S2214-109X(18)30127-X.","journal-title":"Lancet Glob Health"},{"issue":"no. 2","key":"7158_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","volume":"11","author":"X Chen","year":"2023","unstructured":"Chen X, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. J Immunother Cancer. 2023;11(2):e005830. https:\/\/doi.org\/10.1136\/jitc-2022-005830.","journal-title":"J Immunother Cancer"},{"key":"7158_CR8","doi-asserted-by":"publisher","first-page":"S1292","DOI":"10.1016\/j.annonc.2020.10.148","volume":"31","author":"J Liu","year":"2020","unstructured":"Liu J, Li Z, Fu X, Yang Y, Li H, Chen Y. 127p a prospective phase II clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): preliminary results. Ann Oncol. 2020;31:S1292. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.148.","journal-title":"Ann Oncol"},{"issue":"no. 3","key":"7158_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291. https:\/\/doi.org\/10.1136\/jitc-2021-004291.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"7158_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.21037\/jgo-22-131","volume":"13","author":"L Gao","year":"2022","unstructured":"Gao L, Lu J, Zhang P, Hong Z-N, Kang M. Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2). J Gastrointest Oncol. 2022;13(2):478\u201387. https:\/\/doi.org\/10.21037\/jgo-22-131.","journal-title":"J Gastrointest Oncol"},{"issue":"no. 3","key":"7158_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, et al. Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2024;167(3):838-847.e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"7158_CR12","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30(9):2549\u201357. https:\/\/doi.org\/10.1038\/s41591-024-03064-w.","journal-title":"Nat Med"},{"issue":"6","key":"7158_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/SLA.0000000000004238","volume":"275","author":"T Hagi","year":"2022","unstructured":"Hagi T, et al. Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery. Ann Surg. 2022;275(6):1121. https:\/\/doi.org\/10.1097\/SLA.0000000000004238.","journal-title":"Ann Surg"},{"issue":"5","key":"7158_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/SLA.0000000000005636","volume":"276","author":"IYH Wong","year":"2022","unstructured":"Wong IYH, et al. A novel tumor staging system incorporating tumor regression grade (TRG) with lymph node status (ypN-category) results in better prognostication than ypTNM stage groups after neoadjuvant therapy for esophageal squamous cell carcinoma. Ann Surg. 2022;276(5):784\u201391. https:\/\/doi.org\/10.1097\/SLA.0000000000005636.","journal-title":"Ann Surg"},{"issue":"6","key":"7158_CR15","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1097\/SLA.0000000000003727","volume":"274","author":"X Leng","year":"2021","unstructured":"Leng X, et al. Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of Esophagus: from the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg. 2021;274(6):e1022\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000003727.","journal-title":"Ann Surg"},{"key":"7158_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","volume":"186","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma. Eur J Cancer. 2023;186:196\u2013210. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.008.","journal-title":"Eur J Cancer"},{"issue":"10","key":"7158_CR17","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.dld.2024.05.011","volume":"56","author":"B Gao","year":"2024","unstructured":"Gao B, Zhao Z, Gao X, Zhang T, Zhang N, Zhang Y. Zhu Y \u2018Role of pathological tumor regression grade of lymph node metastasis following neoadjuvant chemotherapy in locally advanced gastric cancer.\u2019 Dig Liver Dis. 2024;56(10):1768\u201375. https:\/\/doi.org\/10.1016\/j.dld.2024.05.011.","journal-title":"Dig Liver Dis"},{"issue":"11","key":"7158_CR18","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41416-023-02217-x","volume":"128","author":"A Athauda","year":"2023","unstructured":"Athauda A. Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials. Br J Cancer. 2023;128(11):2036\u201343.","journal-title":"Br J Cancer"},{"issue":"28","key":"7158_CR19","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1200\/JCO.23.00139","volume":"41","author":"JL Moore","year":"2023","unstructured":"Moore JL, et al. Pathologic lymph node regression after neoadjuvant chemotherapy predicts recurrence and survival in esophageal adenocarcinoma: a multicenter study in the United Kingdom. J Clin Oncol. 2023;41(28):4522\u201334. https:\/\/doi.org\/10.1200\/JCO.23.00139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7158_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","volume":"12","author":"TW Rice","year":"2017","unstructured":"Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36\u201342. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.016.","journal-title":"J Thorac Oncol"},{"issue":"30","key":"7158_CR21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.22.2083.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7158_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521\u201330. https:\/\/doi.org\/10.1002\/cncr.11660.","journal-title":"Cancer"},{"key":"7158_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-025-03016-2","author":"J Sun","year":"2025","unstructured":"Sun J, et al. \u2018Does pathological complete response after neoadjuvant chemoradiotherapy associate with long-term survival in esophageal cancer: a systematic review and meta-analysis.\u2019 BMC Surg. 2025. https:\/\/doi.org\/10.1186\/s12893-025-03016-2.","journal-title":"BMC Surg"},{"key":"7158_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70676","author":"F Zhao","year":"2025","unstructured":"Zhao F, et al. Multi-institutional analysis of survival and recurrence patterns of different pathological regression types after neoadjuvant chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Cancer Med. 2025. https:\/\/doi.org\/10.1002\/cam4.70676.","journal-title":"Cancer Med"},{"key":"7158_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13465-w","author":"X Duan","year":"2025","unstructured":"Duan X, et al. Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma. BMC Cancer. 2025. https:\/\/doi.org\/10.1186\/s12885-025-13465-w.","journal-title":"BMC Cancer"},{"key":"7158_CR26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14534-9","author":"Y Tian","year":"2023","unstructured":"Tian Y, et al. A comparison of clinicopathologic outcomes and patterns of lymphatic spread across neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma. Ann Surg Oncol. 2023. https:\/\/doi.org\/10.1245\/s10434-023-14534-9.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7158_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10388-025-01128-5","volume":"22","author":"T Hagi","year":"2025","unstructured":"Hagi T, et al. Initial reduction of the primary tumor or lymph nodes: which is the better prognostic factor in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemotherapy followed by surgery? Esophagus. 2025;22(3):398\u2013409. https:\/\/doi.org\/10.1007\/s10388-025-01128-5.","journal-title":"Esophagus"},{"issue":"5","key":"7158_CR28","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1245\/s10434-025-16914-9","volume":"32","author":"X Huang","year":"2025","unstructured":"Huang X, et al. Positive lymph node status before and after neoadjuvant chemoradiotherapy improves prediction of disease-free survival in esophageal squamous cell carcinoma patients. Ann Surg Oncol. 2025;32(5):3147\u201356. https:\/\/doi.org\/10.1245\/s10434-025-16914-9.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7158_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doaa005","volume":"33","author":"F Klevebro","year":"2020","unstructured":"Klevebro F, Tsekrekos A, Low D, Lundell L, Vieth M, Detlefsen S. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus. 2020;33(6):doaa005. https:\/\/doi.org\/10.1093\/dote\/doaa005.","journal-title":"Dis Esophagus"},{"issue":"8","key":"7158_CR30","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.1245\/s10434-025-17264-2","volume":"32","author":"G Capovilla","year":"2025","unstructured":"Capovilla G, et al. Prognostic value of tumor regression grade after chemotherapy versus chemoradiotherapy in patients undergoing neoadjuvant treatment for locally advanced esophageal adenocarcinoma. Ann Surg Oncol. 2025;32(8):5909\u201318. https:\/\/doi.org\/10.1245\/s10434-025-17264-2.","journal-title":"Ann Surg Oncol"},{"issue":"no. 2","key":"7158_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae034","volume":"111","author":"SPG Henckens","year":"2024","unstructured":"Henckens SPG, et al. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. Br J Surg. 2024;111(2):znae034. https:\/\/doi.org\/10.1093\/bjs\/znae034.","journal-title":"Br J Surg"},{"key":"7158_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000713","author":"IF Rompen","year":"2023","unstructured":"Rompen IF, et al. Age dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients. Int J Surg. 2023. https:\/\/doi.org\/10.1097\/js9.0000000000000713.","journal-title":"Int J Surg"},{"issue":"11","key":"7158_CR33","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c","volume":"73","author":"A-M Mandard","year":"1994","unstructured":"Mandard A-M, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19940601)73:11%3c2680::aid-cncr2820731105%3e3.0.co;2-c.","journal-title":"Cancer"},{"issue":"8","key":"7158_CR34","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-010-0995-2","volume":"17","author":"DKH Tong","year":"2010","unstructured":"Tong DKH, Law S, Kwong DLW, Chan KW, Lam AKY, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol. 2010;17(8):2184\u201392. https:\/\/doi.org\/10.1245\/s10434-010-0995-2.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"7158_CR35","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1007\/s00432-022-04366-7","volume":"149","author":"M Adachi","year":"2023","unstructured":"Adachi M, et al. \u2018The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy.\u2019 J Cancer Res Clin Oncol. 2023;149(8):4663\u201373. https:\/\/doi.org\/10.1007\/s00432-022-04366-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"7158_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.21037\/jgo-22-537","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study. J Gastrointest Oncol. 2022;13(3):1046\u201357. https:\/\/doi.org\/10.21037\/jgo-22-537.","journal-title":"J Gastrointest Oncol"},{"issue":"no. 12","key":"7158_CR37","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.4251\/wjgo.v13.i12.2161","volume":"13","author":"Z-N Liu","year":"2021","unstructured":"Liu Z-N, et al. Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy. World J Gastrointest Oncol. 2021;13(12):2161\u201379. https:\/\/doi.org\/10.4251\/wjgo.v13.i12.2161.","journal-title":"World J Gastrointest Oncol"},{"issue":"no. 1","key":"7158_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4143\/crt.2020.516","volume":"53","author":"Y Tong","year":"2021","unstructured":"Tong Y, Zhu Y, Zhao Y, Shan Z, Liu D, Zhang J. Evaluation and comparison of predictive value of tumor regression grades according to Mandard and Becker in locally advanced gastric adenocarcinoma. Cancer Res Treat. 2021;53(1):112\u201322. https:\/\/doi.org\/10.4143\/crt.2020.516.","journal-title":"Cancer Res Treat"},{"issue":"no. 1","key":"7158_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07779-0","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery. BMC Cancer. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12885-020-07779-0.","journal-title":"BMC Cancer"},{"issue":"13","key":"7158_CR40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"},{"issue":"no. 5","key":"7158_CR41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ejso.2021.12.021","volume":"48","author":"RP Evans","year":"2022","unstructured":"Evans RP, Kamarajah SK, Kunene V, Zardo D, Elshafie M, Griffiths EA. Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma. Eur J Surg Oncol. 2022;48(5):1001\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2021.12.021.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"7158_CR42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study\u2019. J Thorac Cardiovasc Surg. 2023;167(3):838\u201347. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"no. 10265","key":"7158_CR43","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"issue":"5","key":"7158_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"key":"7158_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","volume":"138","author":"S Liu","year":"2020","unstructured":"Liu S, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. Eur J Cancer. 2020;138:113\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.002.","journal-title":"Eur J Cancer"},{"issue":"10447","key":"7158_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, et al. \u2018Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.\u2019 Lancet. 2024;404(10447):55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1.","journal-title":"Lancet"},{"issue":"1","key":"7158_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008229","volume":"12","author":"N Jiang","year":"2024","unstructured":"Jiang N, et al. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial. J Immunother Cancer. 2024;12(1):e008229. https:\/\/doi.org\/10.1136\/jitc-2023-008229.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"7158_CR48","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1078-0432.ccr-19-2244","volume":"26","author":"I Spassova","year":"2020","unstructured":"Spassova I, et al. Predominance of central memory T cells with high T-cell receptor repertoire diversity is associated with response to PD-1\/PD-L1 inhibition in Merkel cell carcinoma. Clin Cancer Res. 2020;26(9):2257\u201367. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2244.","journal-title":"Clin Cancer Res"},{"key":"7158_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24343-x","author":"S Valpione","year":"2021","unstructured":"Valpione S, et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/s41467-021-24343-x.","journal-title":"Nat Commun"},{"issue":"4","key":"7158_CR50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26(4):475\u201384. https:\/\/doi.org\/10.1038\/s41591-020-0829-0.","journal-title":"Nat Med"},{"issue":"16","key":"7158_CR51","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/jco.22.02363","volume":"41","author":"P Squifflet","year":"2023","unstructured":"Squifflet P, et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2\u2013positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy. J Clin Oncol. 2023;41(16):2988\u201397. https:\/\/doi.org\/10.1200\/jco.22.02363.","journal-title":"J Clin Oncol"},{"key":"7158_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3","author":"AM Menzies","year":"2021","unstructured":"Menzies AM. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International neoadjuvant melanoma consortium (INMC). Nat Med. 2021. https:\/\/doi.org\/10.1038\/s41591-020-01188-3.","journal-title":"Nat Med"},{"issue":"no. 1","key":"7158_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02660-6.","journal-title":"Nat Med"},{"key":"7158_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7228","author":"H Pan","year":"2024","unstructured":"Pan H, et al. Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer. Cancer Med. 2024. https:\/\/doi.org\/10.1002\/cam4.7228.","journal-title":"Cancer Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07158-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07158-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07158-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:03:49Z","timestamp":1760490229000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07158-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7158"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07158-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1086"}}